

List of Supplementary Materials

1. **Supplementary acknowledgements**

- a. KPMP Contributors List
- b. Members of the Nephrotic Syndrome Study Network (NEPTUNE)

2. **Supplementary Figures**

- a. **Supplementary Figure S1.** Expression levels of module scores in disease and living donor biopsies
- b. **Supplementary Figure S2.** Enriched wiki pathways **and** regulatory potential of predicted target genes
- c. **Supplementary Figure S3.** UMAP of the sixteen spatially localized niches in the 10x Visium spots based on clustering by cell type distribution.
- d. **Supplementary Figure S4.** Integrated unbiased clustering analysis of six CKD visium transcriptomic datasets.

3. **Supplementary Tables**

- a. Supplementary Table S1. Time of biopsy characteristics of participants in KPMP cohort included in this study.
- b. Supplementary Table 2. Time of biopsy characteristics of participants in NEPTUNE included in this study.
- c. Supplementary Table S3. Distribution of arteriolar hyalinosis descriptor scores.
- d. Supplementary Table S4. Correlation of module genes with arteriolar hyalinosis score.
- e. Supplementary Table S5. Enriched pathways along the pseudotime in afferent arteriolar cells.
- f. Supplementary Table S6. Pathway differences in efferent cells with high blue and pink module scores.

Supplementary acknowledgement

KPMP Contributors List

Altos Labs: Blue Lake, Kun Zhang

Beth Israel Deaconess Medical Center: Stewart Lecker; Alexander Morales; Isaac Stillman

Boston Cell Standards: Steve Bogen

Boston Medical Center: Afolarin A. Amodu; Laurence Beck; Joel Henderson; Titlayo Ilori; Shana Maikhor; Ingrid Onul, Insa Schmidt; Ashish Verma; Sushrut Waikar; Pranav Yadati; Guanghao Yu

Brigham and Women's Hospital: Mia R. Colona; Gearoid McMahon; Astrid Weins

Broad Institute: Nir Hacohen; Anna Greka; Paul J. Hoover; Jamie L. Marshall

Case Western Reserve University: Mark Aulisio; William Bush; Yijiang Chen; Dana Crawford; Anant Madabhushi; Vidya S. Viswanathan

Cleveland Clinic: Lakeshia Bush; Leslie Cooperman; Crystal Gadegbeku; Leal Herlitz; Stacey Jolly; Jane Nguyen; Charles O'Malley; John O'Toole; Ellen Palmer; Emilio Poggio; Kassandra Spates-Harden; John Sedor; Dianna Sendrey; Jonathan Taliercio

Columbia University: Paul Appelbaum; Olivia Balderes; Jonathan Barasch; Cecilia Berroue; Andrew Bomback; Pietro A. Canetta; Vivette D'Agati; Krzysztof Kiryluk; Satoru Kudose; Karla Mehl; Maya Sabatello; Ning Shang

Delft University of Technology: Joana de Pinho Gonçalves; Roy Lardenoije; Lukasz Migas; Raf Van de Plas

Duke University: Laura Barisoni

Harvard University: Helmut Rennke

Icahn School of Medicine at Mount Sinai: Evren Azeloglu; Kirk Campbell; Steven Coca; Cijang He; John He; Srinivas Ravi Iyengar; Seanee Lefferts; Girish Nadkarni; Marissa Patel; Joji Tokita; Stephen Ward; Yuguang Xiong

Indiana University: Abraham Verdoes; Angela Sabo; Daria Barwinska; Debora Lidia Gisch; James Williams; Katherine Kelly; Kenneth Dunn; Mahla Asghari; Michael Eadon; Michael Ferkowicz; Pierre Dagher; Ricardo Melo Ferreira; Seth Winfree; Sharon Bledsoe; Stephanie Wofford; Tarek El-Achkar; Timothy Sutton; William Bowen; Ying-Hua Cheng; Austen Slade; Elizabeth Record; Yinghua Cheng

Indian University at Bloomington: Katy Borner, Bruce Herr; Yashvardhan Jain; Ellen Quardokus

Johns Hopkins University: Mohamed Atta; Lauren Bernard; Steven Menez; Chirag Parikh; Celia Pamela Corona Villalobos; Ashley Wang; Yumeng Wen; Alan Xu

Joslin Diabetes Center: Sarah Chen; Isabel Donohoe; Camille Johansen; Sylvia Rosas; Jennifer Sun

KPMP Patient Partner: Joseph Ardayfio; Jack Bebiak; Taneisha Campbell; Monica Fox; Richard Knight; Robert Koewler; Roy Pinkeney; John Saul; Anna Shpigel

Northwestern University: Pottumarthi Prasad

Ohio State University: Sethu M. Madhavan; Samir Parikh; Brad Rovin; John P. Shapiro

Pacific Northwest National Laboratory: Christopher Anderton, Jessica Lukowski; Ljiljana Pasatolic; Dusan Velickovic

Parkland Health: George Oliver

Princeton University: Weiguang Mao; Rachel Sealfon; Olga Troyanskaya; Aaron Wong

Seattle Children's Hospital: Ari Pollack

Stanford University: Yury Goltsev

State University of New York at Buffalo: Brandon Ginley; Brendon Lutnick

University of California at San Diego: Kun Zhang

University of California at San Francisco: Kavya Anjani; Zoltan G. Laszik; Tariq Mukatash; Garry Nolan

University of Arizona: David Beyda; Erika Bracamonte; Frank Brosius; Baltazar Campos; Nicole Marquez; Katherine Mendoza; Raymond Scott; Bijin Thajudeen; Rebecca Tsosie; Gregory Woodhead

University of Chicago: Milda Saunders

University of Cincinnati: Rita R. Alloway; Paul J. Lee; Adele Rike; Tiffany Shi; E. Steve Woodle

University of Colorado: Petter Bjornstad, Elena Hsieh; Jessica Kendrick; Laura Pyle; Joshua Thurman; Carissa Vinovskis; Julia Wrobel

University of Florida: Nicholas Lucarelli; Pinaki Sarder

University of Illinois, Chicago: James Bui; Eunice Carmona-Powell; Ron Gaba; Tanika Kelly; James Lash; Natalie Meza; Devona Redmond; Amada Renteria; Ana Ricardo; Suman Setty; Anand Srivastava

University of Michigan: Fadhl Alakwaa; Heather Ascani; Ul Balis; Markus Bitzer; Victoria Blanc; Nikki Bonevich; Ninive Conser; Dawit Demeke; Rachel Dull; Sean Eddy; Renee Frey; John Hartman; Yongqun Oliver He; Jeffrey Hodgins; Matthias Kretzler; Chrysta Lienczewski; Jinghui Luo; Laura Mariani; Phillip McCown; Rajasree Menon; Viji Nair; Edgar Otto; Rebecca Reamy; Michael Rose; Jennifer Schaub; Becky Steck; Zachary Wright

University of Minnesota: Alyson Coleman; Dorisann Henderson-Brown; Jerica Berge; Maria Luiza Caramori; Oyedele Adeyi; Patrick Nachman; Sami Safadi; Siobhan Flanagan; Sisi Ma; Susan Klett; Susan Wolf; Tasma Harindhanavudhi; Via Rao

University of North Carolina: Peter Bream; Anne Froment; Sara Kelley; Amy Mottl; Prabir Roy-Chaudhury; Evan Zeitler

University of Pittsburgh: Filitsa Bender; Michele Elder; Matthew Gilliam; Daniel E. Hall; John A. Kellum; Raghavan Murugan; Paul Palevsky; Matthew Rosengart; Roderick Tan; Mitchell Tublin; James Winters

University of Texas Health Science Center at San Antonio: Shweta Bansal; Richard Montellano; Annapurna Pamreddy; Kumar Sharma; Manjeri Venkatachalam; Hongping Ye; Guanshi Zhang

University of Texas Southwestern: Mujeeb Basit; Qi Cai; Allen Hendricks; Susan Hedayati; Asra Kermani; Simon C. Lee; Shihong Ma; Richard Tyler Miller; Orson W. Moe; Harold Park; Jiten Patel; Anil Pillai; Kamalanathan Sambandam; Jose Torrealba; Robert D. Toto; Miguel Vazquez; Nancy Wang; Natasha Wen; Dianbo Zhang

University of Washington: Charles Alpers; Ashley Berglund; Brooke Berry; Kristina Blank; Keith Brown; Jonas Carson; Stephen Daniel; Ian H. de Boer; Ashveena L Dighe; Frederick Dowd; Stephanie M. Grewenow; Jonathan Himmelfarb; Andrew Hoofnagle; Nichole Jefferson; Brandon Larson; Christine Limonte; Robyn McClelland; Sean Mooney; Yunbi Nam; Christopher Park; Jimmy Phuong; Kasra Rezaei; Glenda Roberts; Natalya Sarkisova; Stuart Shankland; Jaime Snyder; Christy Stutzke; Katherine Tuttle; Artit Wangperawong; Adam Wilcox; Kayleen Williams; Bessie Young

Vanderbilt University: Jamie Allen; Richard M. Caprioli; Mark de Caestecker; Katerina Djambazova; Martin Dufresne; Melissa Farrow; Agnes Fogo; Kavya Sharman; Jeffrey Spraggins

Washington University St. Louis: Jeannine Basta; Kristine Conlon; Sabine M. Diettman; Joseph Gaut; Madhurima Kaushal; Sanjay Jain; Amanda Knoten; Brittany Minor; Gerald Nwanne; Anitha Vijayan; Bo Zhang

Yale University: Tanima Arora; Lloyd Cantley; Angela M. Victoria Castro; Vijayakumar Kakade; Gilbert Moeckel; Dennis Moledina; Melissa Shaw; Francis P Wilson

Members of the Nephrotic Syndrome Study Network (NEPTUNE)

NEPTUNE Enrolling Centers

Atrium Health Levine Children's Hospital, Charlotte, SC: Susan Massengill*, Layla Lo#
Cleveland Clinic, Cleveland, OH: Katherine Dell*, John Sedor**, Stephanie Larson#
Children's Hospital, Los Angeles, CA: Ian Macumber* Kevin Lemley*, Silpa Sharma#
Children's Mercy Hospital, Kansas City, MO: Tarak Srivastava*, Kelsey Markus#
Cohen Children's Hospital, New Hyde Park, NY: Christine Sethna*, Suzanne Vento #
Columbia University, New York, NY: Pietro Canetta*, Anup Pradhan#
Duke University Medical Center, Durham, NC: Opeyemi Olabasi**, Rasheed Gbadegesin*, Maurice Smith#
Emory University, Atlanta, GA: Laurence Greenbaum*, Chia-shi Wang*, Emily Yun#
The Lundquist Institute, Torrance, CA: Sharon Adler*, Janine LaPage#
John H Stroger Cook County Hospital, Chicago, IL: Amatur Amarah*, Matthew Itteera#
Johns Hopkins Medicine, Baltimore, MD: Meredith Atkinson*, Miahje Williams#
Mayo Clinic, Rochester, MN: John Lieske*, Marie Hogan**
Medical University of South Carolina, David Selewski, Cheryl Alston#*
Montefiore Medical Center, Bronx, NY: Frederick Kaskel*, Kim Reidy**, Michael Ross*, Patricia Flynn#
NIDDK Intramural, Bethesda MD: Jeffrey Kopp*
New York University Medical Center, New York, NY: Laura Malaga-Diequez*, Olga Zhdanova**, Laura Jane Pehrson#, Melanie Miranda#
The Ohio State University College of Medicine, Columbus, OH: Salem Almaani*, Laci Roberts#
Stanford University, Stanford, CA: Richard Lafayette*, Shiktij Dave#
Temple University, Philadelphia, PA: Iris Lee*, Zoey Pfeffer#
Texas Children's Hospital at Baylor College of Medicine, Houston, TX: Shweta Shah*, Aisha Deslandes# #
University Health Network Toronto: Heather Reich*, Michelle Hladunewich**, Paul Ling#, Martin Romano#
University of California at San Francisco, San Francisco, CA: Paul Brakeman*
University of Colorado Anschutz Medical Campus, Aurora, CO: Amber Podoll* Nathan Rogers#
University of Kansas Medical Center, Kansas City, KS: Ellen McCarthy*, Elizabeth Landry#
University of Miami, Miami, FL: Alessia Fornoni*, Carlos Bidot#
University of Michigan, Ann Arbor, MI: M Kretzler*, Laura Mariani*, Zubin Modi*, A Williams#, Meghan Stelzer#
University of Minnesota, Minneapolis, MN: Patrick Nachman*, Michelle Rheault*, Jenna Hanson#
University of North Carolina, Chapel Hill, NC: Vimal Derebail*, Keisha Gibson*, Anne Froment#
University of Pennsylvania, Philadelphia, PA: Lawrence Holzman*, Kevin Meyers**, Krishna Kallem#, Ann Swenson#
University of Texas San Antonio, San Antonio, TX: Samin Sharma*
University of Texas Southwestern, Dallas, TX: Elizabeth Roehm*, Kamalanathan Sambandam*, Jamie Hellewege
University of Washington, Seattle, WA: Ashley Jefferson*, Sangeeta Hingorani**, Katherine Tuttle**§, Linda Manahan #, Emily Pao#, Kelli Kuykendall§
Wake Forest University Baptist Health, Winston-Salem, NC: Jen Jar Lin*
Washington University in St. Louis, St. Louis, MO: Ellen Cody*

Data Analysis and Coordinating Center: Matthias Kretzler*, Laura Barisoni**, Crystal Gadegbeku**, Brenda Gillespie**, Lawrence Holzman**, Laura Mariani**, Zubin Modi**, Matthew G Sampson**, Eloise Salmon**, John Sedor**, Abigail Smith**, Howard Trachtman**, Jarcy Zee**, Gabrielle Alter, Hailey Desmond, Sean Eddy, Damian Fermin, Wenjun Ju, Maria Larkina, Shengqian Li, Shannon Li, Chrysta Lienczewski, Tina Mainieri, Rebecca Scherr, Jonathan Troost, Amanda Williams


Digital Pathology Committee: Carmen Avila-Casado (University Health Network, Toronto), Serena Bagnasco (Johns Hopkins University), Clarissa Cassol (Arakana), Lihong Bu (Mayo Clinic), Shelley Caltharp (Emory University), Dawit Demeke (University of Michigan), Brenda Gillespie (University of Michigan), Jared Hassler (Temple University), Leal Herlitz (Cleveland Clinic), Stephen Hewitt (National Cancer Institute), Jeff Hodgkin (University of Michigan), Danni Holanda (Arkana), Neeraja Kambham (Stanford University), Kevin Lemley (Children's Hospital of Los Angeles), Laura Mariani (University of Michigan), Nidia Messias (Washington University), Alexei Mikhailov (Wake Forest), Behzad Najafian (University of Washington), Matthew Palmer

*Principal Investigator; **Co-investigator; #Study Coordinator; §Providence Medical Research Center, Spokane, WA


Last Update: 18 May 2023

(University of Pennsylvania), Avi Rosenberg (Johns Hopkins University), Virginie Royal (University of Montreal), Barry Stokes (Columbia University), David Thomas (Duke University), Michifumi Yamashita (Cedar Sinai), Hong Yin (Emory University) Jarcy Zee (University of Pennsylvania), Yiqin Zuo (University of Miami)
Co-Chairs: Laura Barisoni (Duke University) and Cynthia Nast (Cedar Sinai).

Supplementary Figure S1. Expression levels of module scores in disease and living donor biopsies. Density violin plot showing the relative expression levels of the module scores calculated for the blue, pink and red gene-sets in disease and living donor biopsies. The samples were down sampled to a total of 250 arteriolar (afferent ad efferent endothelial) cells per group




Supplementary Figure 3 UMAP of the sixteen spatially localized niches in the 10x Visium spots based on clustering by cell type distribution.



Supplementary Figure 4. Integrated unbiased clustering analysis of six CKD visium transcriptomic datasets. a. Heatmap showing the top 5 markers in each cluster.

b. Violin density plot showing the expression of afferent arteriole marker, GJ 4 in the clusters. **c.** Violin density plot showing the expression of efferent arteriole marker, S C in the clusters.



Supplementary Table 1. Time of biopsy characteristics of participants in KPMP cohort included in this study.

Total (N)	48
Age (average years \pm standard deviation)	57.2 \pm 15.2
Sex (%)	
Female	23 (48%)
Male	25 (52%)
Race (N)	
Asian	4
Black or African American	14
White	29
Not reported	1
Disease category (%)	
Acute kidney injury (AKI)	14 (29%)
Diabetic kidney disease (DKD)	26 (54%)
Hypertensive chronic kidney disease (HCKD)	8 (17%)

Supplementary Table 2. Time of biopsy characteristics of participants in NEPTUNE included in this study.

		Total N = 198
Average age in years (SD)		46.2 (+/-15.7)
Average eGFR at biopsy (SD)		69.9 (+/-34.7)
Median UPCR at biopsy [IQR]		4.0 [+/- 5.4]
Average % Interstitial fibrosis (SD)		17.7 (+/-18.6)
Sex		
	Female	75 (38%)
	Male	123 (62%)
Race N (%)		
	Asian	21 (10%)
	Black or African American	51 (26%)
	White	132 (61%)
	Native American/Alaskan, Pacific Islanders/Hawaiian	1 (1%)
	Not reported	5 (2%)
Diagnosis		
	FSGS (%)	70 (35%)
	APOL1 risk allele (%)	39 (20%)
	Immunosuppression pre- biopsy (%)	27 (14%)

Abbreviations: eGFR – estimated glomerular filtration rate; UPCR – urine protein creatinine ratio; FSGS – focal segmental glomerulosclerosis; SD – standard deviation; IQR – interquartile range.

Supplementary Table S3. Distribution of arteriolar hyalinosis descriptor scores. WSI of the formalin-fixed and paraffin-embedded sections from the KPMP cohort were scored for severity of arteriolar hyalinosis using a standardized semiquantitative approach: 0 (none), 1+ (mild), 2+ (moderate), or 3+ (severe)

Arteriolar hyalinosis score	Number (Total N=45)
No (score = 0)	24
Mild (score = 1)	13
Moderate (score = 2)	4
High (score = 3)	4

Supplementary Table S4. Correlation of module genes with arteriolar hyalinosis

score. The WGCNA analysis on the meta cell expression data of the arteriolar endothelial cells yielded three gene sets/modules (blue, pink, and red) with 28, 11 and 12 genes, respectively, positively associated ($p < 0.05$) with arteriolar hyalinosis

genes	moduleColor	correlation	p value
ADGRF5	blue	0.1529	0.0132
CD34	blue	0.1855	0.0026
CD81	blue	0.2482	0.0000
EFNB1	blue	0.1655	0.0073
ENG	blue	0.1316	0.0333
FLT1	blue	0.1292	0.0366
IGFBP4	blue	0.1424	0.0212
IGFBP5	blue	0.1402	0.0233
PBX1	blue	0.1604	0.0093
PDGFB	blue	0.1285	0.0376
PRCP	blue	0.1922	0.0018
SLC6A6	blue	0.1592	0.0099
SLC9A3R2	blue	0.1795	0.0035
TCIM	blue	0.1230	0.0468
THBD	blue	0.1430	0.0206
UNC5B	blue	0.1534	0.0129
ANXA2	pink	0.2039	0.0009
EMP3	pink	0.2869	0.0000
HSPB1	pink	0.2356	0.0001
IL32	pink	0.1789	0.0037
LGALS1	pink	0.2619	0.0000
LMNA	pink	0.2369	0.0001
PLAT	pink	0.2131	0.0005
S100A10	pink	0.2132	0.0005
S100A11	pink	0.2373	0.0001
S100A6	pink	0.3271	0.0000
SH3BGRL3	pink	0.1394	0.0240
DNAJB4	red	0.1963	0.0014
EPAS1	red	0.1613	0.0089
LTBP4	red	0.1476	0.0168
MGP	red	0.2025	0.0010
PLAC9	red	0.1884	0.0022
SLCO2A1	red	0.2253	0.0002
ID2	red	0.1190	0.0544

Supplementary Table S5. Enriched pathways along the pseudotime in afferent arteriolar cells. Enriched wiki pathways for the differentially expressed genes at the end and start of the pseudotime trajectory in afferent arteriolar cells.

Term	Overlap	P-value	Adjusted P-value	Odds Ratio	Combined Score	Genes
Adipogenesis WP236	6/130	0.0001	0.0160	9.1083	85.1544	MEF2A;MBNL1;PTGIS;EPAS1;LIFR;IL6S
ESC Pluripotency Pathways WP3931	5/116	0.0005	0.0391	8.4047	64.3515	T BMP2;LIFR;IL6ST;SMAD6;FGF2
Primary focal segmental glomerulosclerosis (FSGS) WP2572	26390.00	0.0007	0.0391	10.8966	79.2908	ITGB1;JAG1;PODXL;UTRN
TGF-beta Signaling Pathway WP366	5/132	0.0009	0.0391	7.3399	51.8923	MEF2A;ITGB1;FN1;SKIL;MET
Bone morphogenic protein (BMP) signaling and regulation WP1425	44969.00	0.0019	0.0595	36.4752	227.7372	BMP2;SMAD6
Rett syndrome causing genes WP4312	17593.00	0.0024	0.0595	12.2494	73.8937	TCF4;SHANK3;SYN
Senescence and Autophagy in Cancer WP615	4/105	0.0028	0.0595	7.3241	43.0685	E2 IGFBP3;LAMP2;FN1;IL6ST
Gastrin signaling pathway WP4659	4/114	0.0038	0.0595	6.7218	37.5400	ITGB1;JAG1;GNAQ;TCF4
Amplification and Expansion of Oncogenic Pathways as Metastatic Traits WP3678	44974.00	0.0039	0.0595	24.3107	134.6502	JAG1;EPAS1
NOTCH1 regulation of endothelial cell calcification WP3413	44974.00	0.0039	0.0595	24.3107	134.6502	JAG1;GJA5
Regulation of Wnt/B-catenin Signaling by Small Molecule Compounds WP3664	44974.00	0.0039	0.0595	24.3107	134.6502	CSNK1A1;TCF4
TGF-beta receptor signaling in skeletal dysplasias WP4816	21245.00	0.0041	0.0595	10.0172	55.0313	LTBP3;SMAD6;SKIL
Simplified Interaction Map Between LOXL4 and Oxidative Stress Pathway WP3670	44975.00	0.0044	0.0595	22.7901	123.6263	FN1;EXOC6
Novel intracellular components of RIG-I-like receptor (RLR) pathway WP3865	21976.00	0.0045	0.0595	9.6647	52.1723	DDX17;DDX3X;CXC
Lung fibrosis WP3624	23071.00	0.0052	0.0616	9.1801	48.3002	L12 ELN;FGF2;SKIL
mRNA Processing WP411	4/126	0.0054	0.0616	6.0570	31.6777	HNRNPA2B1;HNRN
Angiogenesis WP1539	44981.00	0.0078	0.0842	16.5696	80.4665	PU;SF3B1;SRRM1
Physiological and pathological hypertrophy of the heart WP1528	44982.00	0.0084	0.0858	15.8484	75.6997	TIMP2;FGF2
Wnt/beta-catenin signaling pathway in leukemia WP3658	44983.00	0.0091	0.0858	15.1873	71.3810	LIFR;IL6ST
Eicosanoid Synthesis WP167	44984.00	0.0098	0.0858	14.5791	67.4528	CSNK1A1;RUNX1T1 PTGIS;PTGDS

Regulation of Actin Cytoskeleton WP51	4/150	0.0098	0.0858	5.0552	23.3834	NCKAP1;FN1;MSN; FGF2
Nanoparticle-mediated activation of receptor signaling WP2643	44985.00	0.0105	0.0878	14.0176	63.8669	ITGB1;FN1
Eicosanoid metabolism via cyclooxygenases (COX) WP4719	10990.00	0.0120	0.0960	13.0151	57.5647	PTGIS;PTGDS
Corticotropin-releasing hormone signaling pathway WP2355	34029.00	0.0150	0.1123	6.1108	25.6462	GNAQ;ECE1;TCF4
Signaling of Hepatocyte Growth Factor Receptor WP313	12451.00	0.0153	0.1123	11.3859	47.6264	ITGB1;MET
Neovascularisation processes WP4331	13547.00	0.0179	0.1268	10.4084	41.8639	JAG1;CXCL12
Neural Crest Differentiation WP2064	3/101	0.0187	0.1275	5.6097	22.3177	ITGB1;TCF4;FGF2
Genes controlling nephrogenesis WP4823	15738.00	0.0238	0.1517	8.8825	33.2134	ITGB1;CXCL12
Circadian rhythm related genes WP3594	4/201	0.0258	0.1517	3.7368	13.6679	DDX5;GNAQ;HNRN PU;PTGDS
Prostaglandin Synthesis and Regulation WP98	16469.00	0.0259	0.1517	8.4685	30.9470	PTGIS;PTGDS
Regulation of Microtubule Cytoskeleton WP2038	16834.00	0.0270	0.1517	8.2756	29.9038	DPYSL2;GNAQ
Focal Adhesion-PI3K-Akt-mTOR- signaling pathway WP3932	5/303	0.0270	0.1517	3.1010	11.2031	ITGB1;EPAS1;FN1; FGF2;MET
SARS-CoV-2 altering angiogenesis via NRP1 WP5065	44931.00	0.0274	0.1517	45.1932	162.4933	NRP1
Osteoblast differentiation WP4787	3/118	0.0280	0.1517	4.7763	17.0734	JAG1;BMP2;FGF2 ITGB1;JAG1;IGFBP 3;FN1;S1PR1;TXNI
VEGFA-VEGFR2 Signaling Pathway WP3888	6/432	0.0334	0.1728	2.6107	8.8738	P
Wnt Signaling Pathway WP363	19025.00	0.0338	0.1728	7.2804	24.6595	CSNK1A1;TCF4
TGF-beta Receptor Signaling WP560	19756.00	0.0362	0.1758	6.9996	23.2251	SMAD6;SKIL
Cardiac Hypertrophic Response WP2795	20121.00	0.0375	0.1758	6.8672	22.5558	MEF2A;FGF2
EV release from cardiac cells and their functional effects WP3297	44933.00	0.0382	0.1758	30.1258	98.3467	CXCL12
Glial Cell Differentiation WP2276	44933.00	0.0382	0.1758	30.1258	98.3467	MSN PTPRB;PODXL;SKI
Ectoderm Differentiation WP2858	3/138	0.0416	0.1867	4.0646	12.9246	L
Mesodermal commitment pathway WP2857	3/147	0.0486	0.2129	3.8088	11.5185	BMP2;TCF4;SMA D6
Oncostatin M Signaling Pathway WP2374	23774.00	0.0506	0.2167	5.7743	17.2253	LIFR;IL6ST
Mammary gland development pathway - Involution (Stage 4 of 4) WP2815	44936.00	0.0541	0.2195	20.0808	58.5571	IL6ST
SARS-CoV-2 and COVID-19 Pathway WP4846	44936.00	0.0541	0.2195	20.0808	58.5571	NRP1

RAC1/PAK1/p38/MMP2 Pathway WP3303	24869.00	0.0549	0.2195	5.5110	15.9972	ITGB1;FN1 CALD1;IGFBP3;GN
Myometrial relaxation and contraction pathways WP289	3/156	0.0561	0.2198	3.5832	10.3189	AQ
SRF and miRs in Smooth Muscle Differentiation and Proliferation WP1991	44937.00	0.0594	0.2277	18.0718	51.0257	MEF2A
16p11.2 proximal deletion syndrome WP4949	27061.00	0.0637	0.2336	5.0502	13.9065	IGFBP3;MSN
Mammary gland development pathway - Puberty (Stage 2 of 4) WP2814	44939.00	0.0698	0.2336	15.0583	40.0837	FN1
Cell Differentiation - Index WP2029	44939.00	0.0698	0.2336	15.0583	40.0837	MEF2A
Cell-type Dependent Selectivity of CCK2R Signaling WP3679	44939.00	0.0698	0.2336	15.0583	40.0837	GNAQ
Development of pulmonary dendritic cells and macrophage subsets WP3892	44939.00	0.0698	0.2336	15.0583	40.0837	TCF4
ncRNAs involved in STAT3 signaling in hepatocellular carcinoma WP4337	44939.00	0.0698	0.2336	15.0583	40.0837	IL6ST
Regulatory circuits of the STAT3 signaling pathway WP4538	28522.00	0.0698	0.2336	4.7834	12.7324	LIFR;IL6ST
Somatic sex determination WP4814	44940.00	0.0750	0.2417	13.8993	36.0063	PTGDS
H19 action Rb-E2F1 signaling and CDK-Beta-catenin activity WP3969	44940.00	0.0750	0.2417	13.8993	36.0063	JAG1
MicroRNAs in cardiomyocyte hypertrophy WP1544	30713.00	0.0794	0.2417	4.4321	11.2297	IL6ST;FGF2
EGFR Tyrosine Kinase Inhibitor Resistance WP4806	30713.00	0.0794	0.2417	4.4321	11.2297	FGF2;MET
Mammary gland development pathway - Embryonic development (Stage 1 of 4) WP2813	44941.00	0.0801	0.2417	12.9058	32.5775	ITGB1
FOXP3 in COVID-19 WP5063	44941.00	0.0801	0.2417	12.9058	32.5775	IL6ST
Airway smooth muscle cell contraction WP4962	44943.00	0.0903	0.2420	11.2915	27.1505	GNAQ
Canonical and non-canonical TGF-B signaling WP3874	44943.00	0.0903	0.2420	11.2915	27.1505	BMPR2
Cells and molecules involved in local acute inflammatory response WP4493	44943.00	0.0903	0.2420	11.2915	27.1505	ITGB1
miR-509-3p alteration of YAP1/ECM axis WP3967	44943.00	0.0903	0.2420	11.2915	27.1505	FN1
Nephrogenesis WP5052	44943.00	0.0903	0.2420	11.2915	27.1505	JAG1
GPCRs, Other WP117	33270.00	0.0910	0.2420	4.0821	9.7857	ADGRF5;S1PR1
TGF-B Signaling in Thyroid Cells for Epithelial-Mesenchymal Transition WP3859	44944.00	0.0954	0.2420	10.6267	24.9736	FN1
Transcription co-factors SKI and SKIL protein partners WP4533	44944.00	0.0954	0.2420	10.6267	24.9736	SKIL

MFAP5 effect on permeability and motility of endothelial cells via cytoskeleton rearrangement WP4560	44944.00	0.0954	0.2420	10.6267	24.9736	LPP
LncRNA involvement in canonical Wnt signaling and colorectal cancer WP4258	34366.00	0.0961	0.2420	3.9483	9.2490	CSNK1A1;HNRNPU
Focal Adhesion WP306	3/198	0.0979	0.2420	2.8054	6.5179	ITGB1;FN1;MET
Small cell lung cancer WP4658	35096.00	0.0995	0.2420	3.8639	8.9148	ITGB1;FN1
Small Ligand GPCRs WP247	44945.00	0.1004	0.2420	10.0359	23.0696	S1PR1
Cell Differentiation - Index expanded WP2023	44945.00	0.1004	0.2420	10.0359	23.0696	MEF2A
Overview of nanoparticle effects WP3287	44945.00	0.1004	0.2420	10.0359	23.0696	FN1
Complement system WP2806	35462.00	0.1013	0.2420	3.8231	8.7542	CD93;CSNK1A1
Pathways Regulating Hippo Signaling WP4540	35827.00	0.1030	0.2431	3.7831	8.5977	GNAQ;MET
Serotonin Receptor 2 and ELK-SRF/GATA4 signaling WP732	44946.00	0.1054	0.2455	9.5072	21.3924	GNAQ
7q11.23 copy number variation syndrome WP4932	2/104	0.1137	0.2587	3.5595	7.7388	ELN;SF3B1
miRNA targets in ECM and membrane receptors WP2911	44948.00	0.1153	0.2587	8.6009	18.5799	FN1
PKC-gamma calcium signaling pathway in ataxia WP4760	44948.00	0.1153	0.2587	8.6009	18.5799	GNAQ
Cancer immunotherapy by PD-1 blockade WP4585	44949.00	0.1202	0.2587	8.2095	17.3917	NFAT5
Glutathione metabolism WP100	44949.00	0.1202	0.2587	8.2095	17.3917	GPX3
Hippo-Yap signaling pathway WP4537	44949.00	0.1202	0.2587	8.2095	17.3917	STK38L ITGB1;FN1;FGF2;M
PI3K-Akt signaling pathway WP4172	4/340	0.1209	0.2587	2.1755	4.5959	ET
IL1 and megakaryocytes in obesity WP2865	44950.00	0.1251	0.2616	7.8522	16.3217	TIMP2
Unfolded protein response WP4925	44950.00	0.1251	0.2616	7.8522	16.3217	TXNIP
Signal Transduction of S1P Receptor WP26	44951.00	0.1300	0.2657	7.5246	15.3540	S1PR1
Mammalian disorder of sexual development WP4842	44951.00	0.1300	0.2657	7.5246	15.3540	PTGDS
1q21.1 copy number variation syndrome WP4905	44953.00	0.1396	0.2792	6.9451	13.6744	GJA5
Canonical and non-canonical Notch signaling WP3845	44953.00	0.1396	0.2792	6.9451	13.6744	JAG1
Hippo-Merlin Signaling Dysregulation WP4541	2/120	0.1434	0.2803	3.0743	5.9706	ITGB1;MET
TLR4 Signaling and Tolerance WP3851	44954.00	0.1444	0.2803	6.6875	12.9421	TRAM1
T-Cell Receptor and Co-stimulatory Signaling WP2583	44955.00	0.1491	0.2803	6.4484	12.2703	CSNK1A1

Inflammatory Response Pathway WP453	44956.00	0.1539	0.2803	6.2257	11.6522	FN1
Sphingolipid pathway WP1422	44956.00	0.1539	0.2803	6.2257	11.6522	SERINC1
Matrix Metalloproteinases WP129	44956.00	0.1539	0.2803	6.2257	11.6522	TIMP2
Cell migration and invasion through p75NTR WP4561	44956.00	0.1539	0.2803	6.2257	11.6522	EFNB2
Oligodendrocyte specification and differentiation, leading to myelin components for CNS WP4304	44956.00	0.1539	0.2803	6.2257	11.6522	FGF2
Extracellular vesicle-mediated signaling in recipient cells WP2870	44956.00	0.1539	0.2803	6.2257	11.6522	MET
Gastric Cancer Network 2 WP2363	44957.00	0.1586	0.2861	6.0179	11.0821	RNF144B
White fat cell differentiation WP4149	11689.00	0.1633	0.2861	5.8235	10.5548	MECOM
Ovarian infertility WP34	11689.00	0.1633	0.2861	5.8235	10.5548	SYNE2
Hair Follicle Development: Organogenesis - Part 2 of 3 WP2839	11689.00	0.1633	0.2861	5.8235	10.5548	ITGB1
Endothelin Pathways WP2197	12055.00	0.1679	0.2887	5.6412	10.0659	ECE1
Oxidative Stress WP408	12055.00	0.1679	0.2887	5.6412	10.0659	GPX3
Type 2 papillary renal cell carcinoma WP4241	12420.00	0.1725	0.2939	5.4700	9.6118	EPAS1
The influence of laminopathies on Wnt signaling WP4844	12785.00	0.1771	0.2963	5.3088	9.1889	CSNK1A1
Overview of leukocyte-intrinsic Hippo pathway functions WP4542	12785.00	0.1771	0.2963	5.3088	9.1889	STK38L
Melatonin metabolism and effects WP3298	13516.00	0.1863	0.3033	5.0134	8.4257	ECE1
Factors and pathways affecting insulin- like growth factor (IGF1)-Akt signaling WP3850	13516.00	0.1863	0.3033	5.0134	8.4257	ITGB1
Photodynamic therapy-induced HIF-1 survival signaling WP3614	13516.00	0.1863	0.3033	5.0134	8.4257	IGFBP3
Brain-derived neurotrophic factor (BDNF) signaling pathway WP2380	2/144	0.1904	0.3052	2.5516	4.2316	MEF2A;DPYSL2
Sleep regulation WP3591	13881.00	0.1908	0.3052	4.8776	8.0805	PTGDS
Male infertility WP4673	2/146	0.1945	0.3085	2.5159	4.1199	CDC42BPA;CLU
Calcium Regulation in the Cardiac Cell WP536	2/150	0.2025	0.3164	2.4474	3.9083	GJA5;GNAQ
Integrated breast cancer pathway WP1984	2/152	0.2066	0.3164	2.4146	3.8080	BMPR2;SMAD6
Hepatitis B infection WP4666	2/152	0.2066	0.3164	2.4146	3.8080	DDX3X;HSPG2
Fas ligand pathway and stress induction of heat shock proteins WP314	15342.00	0.2086	0.3164	4.4009	6.8970	SPTAN1
Breast cancer pathway WP4262	2/154	0.2106	0.3164	2.3825	3.7112	CSNK1A1;FGF2
IL-6 signaling pathway WP364	15707.00	0.2130	0.3164	4.2959	6.6428	IL6ST
Interleukin-11 Signaling Pathway WP2332	16072.00	0.2174	0.3164	4.1958	6.4027	IL6ST
Heart Development WP1591	16072.00	0.2174	0.3164	4.1958	6.4027	BMPR2

Hedgehog Signaling Pathway WP4249	16072.00	0.2174	0.3164	4.1958	6.4027	CSNK1A1
Renin-angiotensin-aldosterone system (RAAS) WP4756	16072.00	0.2174	0.3164	4.1958	6.4027	GNAQ
Nephrotic syndrome WP4758	16438.00	0.2218	0.3164	4.1002	6.1755	PODXL
Notch Signaling WP268	16438.00	0.2218	0.3164	4.1002	6.1755	JAG1
Epithelial to mesenchymal transition in colorectal cancer WP4239	2/160	0.2228	0.3164	2.2914	3.4401	JAG1;FN1
Envelope proteins and their potential roles in EDMD physiopathology WP4535	16803.00	0.2261	0.3164	4.0089	5.9605	SYNE2
Mechanoregulation and pathology of YAP/TAZ via Hippo and non-Hippo mechanisms WP4534	17168.00	0.2304	0.3164	3.9215	5.7567	ITGB1
Development of ureteric collection system WP5053	17168.00	0.2304	0.3164	3.9215	5.7567	ITGB1
NO/cGMP/PKG mediated Neuroprotection WP4008	17168.00	0.2304	0.3164	3.9215	5.7567	PDE3A
Energy Metabolism WP1541	17168.00	0.2304	0.3164	3.9215	5.7567	MEF2A
Differentiation Pathway WP2848	17533.00	0.2347	0.3175	3.8379	5.5632	FGF2
Exercise-induced Circadian Regulation WP410	17533.00	0.2347	0.3175	3.8379	5.5632	NCKAP1
Hepatitis C and Hepatocellular Carcinoma WP3646	17899.00	0.2389	0.3209	3.7578	5.3795	PODXL
Synaptic signaling pathways associated with autism spectrum disorder WP4539	18264.00	0.2432	0.3242	3.6809	5.2048	SHANK3
Copper homeostasis WP3286	18994.00	0.2516	0.3306	3.5362	4.8801	XAF1
One-carbon metabolism and related pathways WP3940	18994.00	0.2516	0.3306	3.5362	4.8801	GPX3
Cardiac Progenitor Differentiation WP2406	19360.00	0.2557	0.3314	3.4680	4.7291	FGF2
Phosphodiesterases in neuronal function WP4222	19360.00	0.2557	0.3314	3.4680	4.7291	PDE3A
The Overlap Between Signal Transduction Pathways that Contribute to a Range of LMNA Laminopathies WP4879	20090.00	0.2640	0.3350	3.3392	4.4473	CSNK1A1
Pathogenic Escherichia coli infection WP2272	20090.00	0.2640	0.3350	3.3392	4.4473	ITGB1
Hematopoietic Stem Cell Differentiation WP2849	20090.00	0.2640	0.3350	3.3392	4.4473	CD34
Vitamin D Receptor Pathway WP2877	2/182	0.2680	0.3377	2.0091	2.6457	IGFBP3;TIMP2
Ras signaling WP4223	2/184	0.2721	0.3406	1.9868	2.5861	RAPGEF5;MET
Complement and Coagulation Cascades WP558	21186.00	0.2762	0.3434	3.1630	4.0695	CLU
MET in type 1 papillary renal cell carcinoma WP4205	21551.00	0.2802	0.3461	3.1083	3.9541	MET

Notch Signaling Pathway Netpath WP61	22282.00	0.2882	0.3536	3.0044	3.7374	JAG1
Endometrial cancer WP4155	23012.00	0.2961	0.3608	2.9072	3.5379	FGF2
Endochondral Ossification with Skeletal Dysplasias WP4808	23377.00	0.3001	0.3608	2.8609	3.4439	FGF2
Endochondral Ossification WP474	23377.00	0.3001	0.3608	2.8609	3.4439	FGF2
AGE/RAGE pathway WP2324	24108.00	0.3078	0.3608	2.7726	3.2667	MSN
Association Between Physico-Chemical Features and Toxicity Associated Pathways WP3680	24108.00	0.3078	0.3608	2.7726	3.2667	FN1
Thyroid stimulating hormone (TSH) signaling pathway WP2032	24108.00	0.3078	0.3608	2.7726	3.2667	GNAQ
SARS-CoV-2 innate immunity evasion and cell-specific immune response WP5039	24108.00	0.3078	0.3608	2.7726	3.2667	CXCL12
Folate Metabolism WP176	25204.00	0.3193	0.3719	2.6499	3.0249	GPX3
MECP2 and Associated Rett Syndrome WP3584	26299.00	0.3306	0.3826	2.5375	2.8084	FGF2
Chromosomal and microsatellite instability in colorectal cancer WP4216	26665.00	0.3344	0.3840	2.5021	2.7412	CSNK1A1
Ciliary landscape WP4352	2/216	0.3375	0.3840	1.6870	1.8323	DDX5;EXOC6
Arrhythmogenic Right Ventricular Cardiomyopathy WP2118	27030.00	0.3381	0.3840	2.4677	2.6763	ITGB1
Prolactin Signaling Pathway WP2037	27760.00	0.3454	0.3899	2.4017	2.5529	ITGB1
Glioblastoma signaling pathways WP2261	29952.00	0.3670	0.4118	2.2231	2.2284	MET
Alzheimer's disease WP2059	30317.00	0.3705	0.4132	2.1959	2.1801	GNAQ
Pathways in clear cell renal cell carcinoma WP4018	31048.00	0.3775	0.4185	2.1434	2.0879	RAPGEF5
ncRNAs involved in Wnt signaling in hepatocellular carcinoma WP4336	31413.00	0.3810	0.4198	2.1181	2.0438	CSNK1A1
Selenium Micronutrient Network WP15	32509.00	0.3913	0.4260	2.0456	1.9193	GPX3
Allograft Rejection WP2328	32509.00	0.3913	0.4260	2.0456	1.9193	CXCL12
G Protein Signaling Pathways WP35	33970.00	0.4048	0.4381	1.9562	1.7693	GNAQ
Integrin-mediated Cell Adhesion WP185	1/101	0.4308	0.4636	1.7990	1.5150	ITGB1
IL-18 signaling pathway WP4754	2/272	0.4470	0.4782	1.3333	1.0735	MEF2A;FN1
Wnt signaling WP428	1/115	0.4737	0.5038	1.5770	1.1783	CSNK1A1
Spinal Cord Injury WP2431	1/118	0.4825	0.5102	1.5363	1.1198	EFNB2
Ebola Virus Pathway on Host WP4217	1/129	0.5134	0.5398	1.4035	0.9358	ITGB1
Regulation of toll-like receptor signaling pathway WP1449	1/139	0.5399	0.5644	1.3011	0.8020	SMAD6
Endoderm differentiation WP2853	1/141	0.5450	0.5666	1.2824	0.7783	TCF4
NRF2 pathway WP2884	1/146	0.5576	0.5764	1.2379	0.7231	GPX3

Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways WP706	1/158	0.5864	0.6028	1.1426	0.6099 ECE1
EGF/EGFR signaling pathway WP437	1/162	0.5956	0.6088	1.1139	0.5773 MEF2A
Chemokine signaling pathway WP3929	1/164	0.6001	0.6100	1.1002	0.5619 CXCL12
Metapathway biotransformation Phase I and II WP702	1/183	0.6405	0.6476	0.9844	0.4385 GPX3
MAPK Signaling Pathway WP382	1/246	0.7478	0.7519	0.7289	0.2118 FGF2
Nuclear Receptors Meta-Pathway WP2882	1/319	0.8330	0.8330	0.5595	0.1022 GPX3

Supplementary Table S6. Pathway differences in efferent cells with high blue and pink module scores.

Enriched wiki pathways for the differentially expressed genes between efferent arteriolar cells with high blue module scores and high pink module scores.

ID	Description	GeneRatio	Bg Ratio	pvalue	p.adjust	qvalue	geneID	Count	
WP4816	WP4816	TGF-beta receptor signaling in skeletal dysplasias	7/172	59/8085	0.0002	0.0002	0.061951529	6497/7048/6498/4054/4093/4091/2033	7
WP2572	WP2572	Primary focal segmental glomerulosclerosis	7/172	72/8085	0.0008	0.0008	0.091453934	950/23607/5747/7099/4040/64423/5	7
WP560	WP560	TGF-beta receptor signaling	6/172	55/8085	0.0010	0.0010	0.091453934	6497/7048/6498/4093/4091/20333791/5747/2321/5	6
WP1539	WP1539	Angiogenesis	4/172	24/8085	0.0015	0.0015	0.099520346	335	4
WP313	WP313	Hepatocyte growth factor receptor signaling	4/172	34/8085	0.0056	0.0056	0.220889754	3672/5747/2889/5829	4
WP5144	WP5144	NRP1-triggered signaling pathways in pancreatic cancer	5/172	54/8085	0.0056	0.0056	0.220889754	7048/3791/1105/5747/2321	5
WP411	WP411	mRNA processing	8/172	128/8085	0.0059	0.0059	0.220889754	6421/10181/8899/10658/23405/2521	8
WP366	WP366	TGF-beta signaling pathway	8/172	133/8085	0.0073	0.0073	0.24228658	6497/7048/6498/9765/7071/5747/64750/2033	8
WP306	WP306	Focal adhesion	10/172	198/8085	0.0095	0.0095	0.268837463	8503/10188/3791/3672/5747/2889/80310/3678/5829/2321	10
WP3888	WP3888	VEGFA-VEGFR2 signaling	17/172	436/8085	0.0112	0.0112	0.268837463	10628/3791/253260/4646/2887/5747/2889/51564/91010/5829/2321/8650/2899/5335/23476/2130/9510	17
WP2369	WP2369	Histone modifications	5/172	65/8085	0.0121	0.0121	0.268837463	55870/64324/5850	5
WP3931	WP3931	Embryonic stem cell pluripotency pathways	7/172	117/8085	0.0122	0.0122	0.268837463	8/51111/429710097/659/3977/324/4040/4093/409	7
WP3658	WP3658	Wnt/beta-catenin signaling pathway in leukemia	3/172	26/8085	0.0172	0.0172	0.330291602	324/4040/3728	3
WP2643	WP2643	Nanoparticle-mediated activation of receptor signaling	3/172	28/8085	0.0210	0.0210	0.330291602	3672/5747/5829	3

WP4217	WP4217	Ebola virus infection in host	7/172	131/8085	0.0215	0.0215	0.330291602	8503/5610/3672/7099/3678/2621/2033	7
WP437	WP437	EGF/EGFR signaling pathway	8/172	162/8085	0.0221	0.0221	0.330291602	9922/10188/253260/2887/6197/5747/9101/5335	8
WP236	WP236	Adipogenesis	7/172	132/8085	0.0223	0.0223	0.330291602	658	7
WP4747	WP4747	Netrin-UNC5B signaling pathway	4/172	52/8085	0.0243	0.0243	0.330291602	249/3791/5747/23365	4
WP3844	WP3844	PI3K-AKT-mTOR signaling pathway and therapeutic opportunities	3/172	30/8085	0.0252	0.0252	0.330291602	8503/253260/2887	3
WP2864	WP2864	Apoptosis-related network due to altered Notch3 in ovarian cancer	4/172	53/8085	0.0258	0.0258	0.330291602	5747/3309/8065/5585	4
WP4868	WP4868	Type I interferon induction and signaling during SARS-CoV-2 infection	3/172	31/8085	0.0275	0.0275	0.330291602	5610/7099/103796421/9967/196/7071/23064/4297/59	3
WP3594	WP3594	Circadian rhythm genes	9/172	201/8085	0.0275	0.0275	0.330291602	27/463/2033	9
WP4172	WP4172	PI3K-Akt signaling pathway	13/172	340/8085	0.0291	0.0291	0.331650568	8503/5586/1435/3791/3672/5747/7099/80310/3678/2321/10161/3643/5585	13
WP3995	WP3995	Prion disease pathway	3/172	33/8085	0.0324	0.0324	0.331650568	5747/3309/2033	3
WP4806	WP4806	EGFR tyrosine kinase inhibitor resistance	5/172	84/8085	0.0330	0.0330	0.331650568	8503/3791/80310/2621/5335	5
WP4241	WP4241	Type 2 papillary renal cell carcinoma	3/172	34/8085	0.0350	0.0350	0.331650568	6421/2034/2033	3
WP4659	WP4659	Gastrin signaling pathway	6/172	115/8085	0.0357	0.0357	0.331650568	8503/5747/51564/5829/5583/5335	6
WP4018	WP4018	Clear cell renal cell carcinoma pathways	5/172	86/8085	0.0360	0.0360	0.331650568	55193/3791/2887/2321/2033	5
WP304	WP304	Kit receptor signaling pathway	4/172	59/8085	0.0364	0.0364	0.331650568	2887/6197/5335/2033	4
WP61	WP61	Notch signaling pathway	4/172	61/8085	0.0404	0.0404	0.332163148	23013/84441/8650	4

WP4787	WP4787	Osteoblast differentiation and related diseases	6/172	119/8085	0.0411	0.0411	0.332163148	8503/659/5286/40 40/4093/5583	6
WP51	WP51	Regulation of actin cytoskeleton	7/172	152/8085	0.0432	0.0432	0.332163148	8503/1131/3672/3 24/5747/5286/582	7
WP4844	WP4844	Influence of laminopathies on Wnt signaling	3/172	37/8085	0.0434	0.0434	0.332163148	26092/324/23405	3
WP619	WP619	Type II interferon signaling	3/172	37/8085	0.0434	0.0434	0.332163148	5610/10379/4261	3
WP4541	WP4541	Hippo-Merlin signaling dysregulation	6/172	121/8085	0.0440	0.0440	0.332163148	3791/3672/5747/3 678/2321/3643	6
WP2374	WP2374	Oncostatin M signaling pathway	4/172	65/8085	0.0492	0.0492	0.351074243	3977/253260/5829 /5583	4
WP3651	WP3651	Pathways affected in adenoid cystic carcinoma	4/172	65/8085	0.0492	0.0492	0.351074243	55914/64324/5850 8/2033	4
WP3680	WP3680	Physico-chemical features and toxicity-associated pathways	4/172	66/8085	0.0515	0.0515	0.358093124	10097/324/5747/5 335	4
WP481	WP481	Insulin signaling	7/172	160/8085	0.0543	0.0543	0.367779335	8503/2887/6197/2 889/5286/5583/36 43	7
WP4540	WP4540	Hippo signaling regulation pathways	5/172	98/8085	0.0575	0.0575	0.379677165	23683/3791/2321/ 5583/3643	5
WP3915	WP3915	Angiopoietin-like protein 8 regulatory pathway	6/172	132/8085	0.0622	0.0622	0.400716547	8503/253260/6197 /2889/5286/3643	6
WP185	WP185	Integrin-mediated cell adhesion	5/172	102/8085	0.0660	0.0660	0.411739879	3672/5747/2889/3 678/5829	5
WP3584	WP3584	MECP2 and associated Rett syndrome	4/172	73/8085	0.0695	0.0695	0.411739879	23435/5978/4204/ 2521	4
WP4300	WP4300	Extracellular vesicles in the crosstalk of cardiac cells	2/172	21/8085	0.0726	0.0726	0.411739879	3791/7099	2
WP4535	WP4535	Envelope proteins and their potential roles in EDMD physiopathology	3/172	46/8085	0.0739	0.0739	0.411739879	23345/196883/232 24	3
WP4861	WP4861	Endoplasmic reticulum stress response in coronavirus infection	3/172	46/8085	0.0739	0.0739	0.411739879	5610/5514/3309	3
WP2586	WP2586	Aryl hydrocarbon receptor pathway	3/172	47/8085	0.0777	0.0777	0.411739879	135112/196/2033	3

WP4312	WP4312	Rett syndrome causing genes	3/172	48/8085	0.0817	0.0817	0.411739879	4204/23224/85358	3
WP4725	WP4725	Sphingolipid metabolism overview	2/172	23/8085	0.0851	0.0851	0.411739879	8613/10558	2
WP4925	WP4925	Unfolded protein response	2/172	23/8085	0.0851	0.0851	0.411739879	10628/3309	2
WP5044	WP5044	Kynurenine pathway and links to cell senescence	2/172	23/8085	0.0851	0.0851	0.411739879	196/7099	2
WP5181	WP5181	Roles of ceramides in development of insulin resistance	2/172	23/8085	0.0851	0.0851	0.411739879	5610/3643 5928/1435/25937/ 3791/3672/324/58 508/6197/5747/80 310/4040/2321/36	2
WP5087	WP5087	Malignant pleural mesothelioma	14/172	440/8085	0.0853	0.0853	0.411739879	43/9510	14
WP4758	WP4758	Nephrotic syndrome	3/172	49/8085	0.0857	0.0857	0.411739879	950/23607/64423	3
WP5300	WP5300	TROP2 regulatory signaling	3/172	49/8085	0.0857	0.0857	0.411739879	5747/3678/8650 5286/5583/5335/2	3
WP2261	WP2261	Glioblastoma signaling pathways	4/172	83/8085	0.1002	0.1002	0.472542808	033	4
WP4726	WP4726	Sphingolipid metabolism: integrated pathway	2/172	26/8085	0.1049	0.1049	0.486341206	8613/10558 1435/2034/3791/5 747/5286/80310/3 678/2321/10161/3	2
WP3932	WP3932	Focal adhesion: PI3K-Akt-mTOR-signaling pathway	10/172	302/8085	0.1098	0.1098	0.500299271	643	10
WP5036	WP5036	Angiotensin II receptor type 1 pathway	2/172	28/8085	0.1188	0.1188	0.523043523	7048/80310	2
WP5284	WP5284	Cell interactions of the pancreatic cancer microenvironment	2/172	28/8085	0.1188	0.1188	0.523043523	1435/3791	2
WP4239	WP4239	Epithelial to mesenchymal transition in colorectal cancer	6/172	162/8085	0.1311	0.1311	0.549308366	5928/8503/7048/4 040/3678/3728 23683/11215/1968	6
WP35	WP35	G protein signaling pathways	4/172	92/8085	0.1322	0.1322	0.549308366	83/5583	4
WP1422	WP1422	Sphingolipid pathway	2/172	30/8085	0.1331	0.1331	0.549308366	10558/10087	2
WP2870	WP2870	Extracellular vesicle-mediated signaling in recipient cells	2/172	30/8085	0.1331	0.1331	0.549308366	7048/324	2
WP2355	WP2355	Corticotropin-releasing hormone signaling pathway	4/172	93/8085	0.1360	0.1360	0.552630495	335 5747/7099/3728/5	4

WP3414	WP3414	Initiation of transcription and translation elongation at the HIV-1 LTR	2/172	32/8085	0.1477	0.1477	0.553934466	51564/2033	2
WP5072	WP5072	Modulators of TCR signaling and T cell activation	3/172	63/8085	0.1499	0.1499	0.553934466	8525/8065/5335	3
WP5222	WP5222	2q13 copy number variation syndrome	3/172	63/8085	0.1499	0.1499	0.553934466	1435/5747/2621	3
WP474	WP474	Endochondral ossification	3/172	64/8085	0.1550	0.1550	0.553934466	249/871/9510	3
WP4808	WP4808	Endochondral ossification with skeletal dysplasias	3/172	64/8085	0.1550	0.1550	0.553934466	249/871/9510	3
WP4786	WP4786	Type I collagen synthesis in the context of osteogenesis imperfecta	2/172	33/8085	0.1551	0.1551	0.553934466	871/4040	2
WP4880	WP4880	Host-pathogen interaction of human coronaviruses - interferon induction	2/172	33/8085	0.1551	0.1551	0.553934466	5610/10379	2
WP4950	WP4950	16p11.2 distal deletion syndrome	2/172	33/8085	0.1551	0.1551	0.553934466	3791/3643	2
WP5088	WP5088	Prostaglandin signaling	2/172	33/8085	0.1551	0.1551	0.553934466	1435/196	2
WP4874	WP4874	CAMKK2 pathway	2/172	34/8085	0.1627	0.1627	0.565472208	1131/2033	2
WP5117	WP5117	Cohesin complex - Cornelia de Lange syndrome	2/172	34/8085	0.1627	0.1627	0.565472208	324/23047	2
WP399	WP399	Wnt signaling pathway and pluripotency	4/172	102/8085	0.1720	0.1720	0.573105498	324/4040/5583/2033	4
WP4630	WP4630	Measles virus infection	5/172	139/8085	0.1742	0.1742	0.573105498	8503/103/5610/7099/10379	5
WP3303	WP3303	RAC1/PAK1/p38/MM P2 pathway	3/172	68/8085	0.1758	0.1758	0.573105498	7075/5747/5829	3
WP4685	WP4685	Melanoma	3/172	68/8085	0.1758	0.1758	0.573105498	8503/3791/80243	3
WP5083	WP5083	Neuroinflammation and glutamatergic signaling	5/172	140/8085	0.1777	0.1777	0.573105498	84230/2744/7048/3597/3643	5
WP3850	WP3850	Factors and pathways affecting insulin-like growth factor (IGF1)-Akt signaling	2/172	36/8085	0.1779	0.1779	0.573105498	3488/253260	2
WP2858	WP2858	Ectoderm differentiation	5/172	142/8085	0.1849	0.1849	0.579208639	6498/4204/5787/3728/8675	5

WP4331	WP4331	Neovascularisation processes	2/172	37/8085	0.1856	0.1856	0.579208639	3791/4093	2
WP4906	WP4906	3q29 copy number variation syndrome	3/172	71/8085	0.1919	0.1919	0.579208639	8503/9857/5829	3
WP2380	WP2380	Brain-derived neurotrophic factor (BDNF) signaling pathway	5/172	144/8085	0.1923	0.1923	0.579208639	249/57498/324/61 97/5335	5
WP4829	WP4829	mBDNF and proBDNF regulation of GABA neurotransmission	2/172	38/8085	0.1933	0.1933	0.579208639	8503/5335	2
WP524	WP524	G13 signaling pathway	2/172	38/8085	0.1933	0.1933	0.579208639	10188/5585 23369/196/9101/3	2
WP4673	WP4673	Male infertility Parkin-ubiquitin proteasomal system pathway	5/172	145/8085	0.1960	0.1960	0.579208639	643/2033	5
WP2359	WP2359	Head and neck squamous cell carcinoma	3/172	72/8085	0.1973	0.1973	0.579208639	5707/25897/3309	3
WP4674	WP4674	Microglia pathogen phagocytosis pathway	3/172	74/8085	0.2083	0.2083	0.599038556	7048/253260/8650	3
WP3937	WP3937	DNA damage response (only ATM dependent)	2/172	40/8085	0.2089	0.2089	0.599038556	8503/5286	2
WP710	WP710	Arrhythmogenic right ventricular cardiomyopathy	4/172	111/8085	0.2109	0.2109	0.599038556	43 8503/324/5286/36	4
WP2118	WP2118	Burn wound healing Neural crest cell migration in cancer	3/172	75/8085	0.2138	0.2138	0.601026849	3672/3678/3728 3791/7099/871/23	3
WP5055	WP5055	Neurodegeneration with brain iron accumulation (NBIA) subtypes pathway	4/172	113/8085	0.2198	0.2198	0.611370006	476	4
WP4565	WP4565	Genes controlling nephrogenesis	2/172	43/8085	0.2325	0.2325	0.636917476	8503/57498	2
WP4577	WP4577	Clock-controlled autophagy in bone metabolism	2/172	44/8085	0.2404	0.2404	0.636917476	4204/10558	2
WP4823	WP4823	Myometrial relaxation and contraction pathways	2/172	44/8085	0.2404	0.2404	0.636917476	3791/23607	2
WP5205	WP5205	Notch signaling	3/172	80/8085	0.2420	0.2420	0.636917476	1435/659/4093 3488/8525/196883	3
WP289	WP289		5/172	157/8085	0.2422	0.2422	0.636917476	/5583/5335	5
WP268	WP268		2/172	45/8085	0.2483	0.2483	0.636917476	3955/8650	2

WP2873	WP2873	Aryl hydrocarbon receptor pathway	2/172	45/8085	0.2483	0.2483	0.636917476	196/2033	2
WP5283	WP5283	Chronic hyperglycemia impairment of neuron function	2/172	45/8085	0.2483	0.2483	0.636917476	23683/5583	2
WP2038	WP2038	Microtubule cytoskeleton regulation	2/172	46/8085	0.2562	0.2562	0.65093373	324/57551	2
WP4971	WP4971	Phosphoinositides metabolism	2/172	49/8085	0.2800	0.2800	0.703915716	5286/5335	2
WP4559	WP4559	Interactions between immune cells and microRNAs in tumor microenvironment	2/172	50/8085	0.2879	0.2879	0.703915716	7048/7099	2
WP363	WP363	Wnt signaling pathway	2/172	51/8085	0.2959	0.2959	0.703915716	324/4040	2
WP4539	WP4539	Synaptic signaling pathways associated with autism spectrum disorder	2/172	51/8085	0.2959	0.2959	0.703915716	8503/85358	2
WP3286	WP3286	Copper homeostasis	2/172	52/8085	0.3038	0.3038	0.703915716	324/54739	2
WP673	WP673	ErbB signaling pathway	3/172	92/8085	0.3115	0.3115	0.703915716	8503/5747/5335	3
WP585	WP585	Interferon type I signaling pathways	2/172	54/8085	0.3195	0.3195	0.703915716	2889/10379	2
WP2018	WP2018	RANKL/RANK signaling pathway	2/172	55/8085	0.3274	0.3274	0.703915716	5747/5335	2
WP5124	WP5124	Alzheimer's disease	7/172	264/8085	0.3306	0.3306	0.703915716	3	7
WP4879	WP4879	Overlap between signal transduction pathways contributing to LMNA laminopathies	2/172	57/8085	0.3430	0.3430	0.703915716	324/23405	2
WP5265	WP5265	Neurogenesis regulation in the olfactory epithelium	2/172	57/8085	0.3430	0.3430	0.703915716	4204/8650	2
WP23	WP23	B cell receptor signaling pathway	3/172	98/8085	0.3466	0.3466	0.703915716	2969/2889/5335	3
WP2507	WP2507	Nanomaterial induced apoptosis	1/172	20/8085	0.3499	0.3499	0.703915716	8837	1
WP3640	WP3640	Imatinib and chronic myeloid leukemia	1/172	20/8085	0.3499	0.3499	0.703915716	2321	1
WP5223	WP5223	2q21.1 copy number variation syndrome	1/172	20/8085	0.3499	0.3499	0.703915716	324	1
WP4223	WP4223	Ras signaling	5/172	184/8085	0.3540	0.3540	0.703915716	8503/3791/2321/5 335/3643	5

WP5236	WP5236	Markers of kidney cell lineage	2/172	59/8085	0.3585	0.3585	0.703915716	3791/79633	2
WP3657	WP3657	Hematopoietic stem cell gene regulation by GABP alpha/beta complex	1/172	21/8085	0.3637	0.3637	0.703915716	2033	1
WP5053	WP5053	Development of ureteric collection system	2/172	60/8085	0.3662	0.3662	0.703915716	659/79633	2
WP558	WP558	Complement and coagulation cascades	2/172	60/8085	0.3662	0.3662	0.703915716	2157/7056	2
WP3945	WP3945	TYROBP causal network in microglia	2/172	61/8085	0.3739	0.3739	0.703915716	375035/3597	2
WP1584	WP1584	Type II diabetes mellitus	1/172	22/8085	0.3773	0.3773	0.703915716	3643	1
WP272	WP272	Blood clotting cascade	1/172	22/8085	0.3773	0.3773	0.703915716	2157	1
WP3599	WP3599	Transcription factor regulation in adipogenesis	1/172	22/8085	0.3773	0.3773	0.703915716	3643	1
WP4722	WP4722	Glycerolipids and glycerophospholipids	1/172	22/8085	0.3773	0.3773	0.703915716	8525	1
WP5111	WP5111	Familial hyperlipidemia type 4	1/172	22/8085	0.3773	0.3773	0.703915716	6400	1
WP5194	WP5194	Synthesis of ceramides and 1-deoxyceramides	1/172	22/8085	0.3773	0.3773	0.703915716	10558	1
WP5180	WP5180	DYRK1A	2/172	62/8085	0.3815	0.3815	0.703915716	5928/5978	2
WP1544	WP1544	MicroRNAs in cardiomyocyte hypertrophy	3/172	104/8085	0.3816	0.3816	0.703915716	8503/4040/51564	3
WP4155	WP4155	Endometrial cancer	2/172	63/8085	0.3891	0.3891	0.703915716	8503/324	2
WP2509	WP2509	Nanoparticle triggered autophagic cell death	1/172	23/8085	0.3906	0.3906	0.703915716	3643	1
WP4197	WP4197	Immune response to tuberculosis	1/172	23/8085	0.3906	0.3906	0.703915716	10379	1
WP4357	WP4357	NRF2-ARE regulation	1/172	23/8085	0.3906	0.3906	0.703915716	3643	1
WP4790	WP4790	FGF23 signaling in hypophosphatemic rickets and related disorders	1/172	23/8085	0.3906	0.3906	0.703915716	249	1
WP4830	WP4830	GDNF/RET signaling axis	1/172	23/8085	0.3906	0.3906	0.703915716	79633	1
WP4942	WP4942	15q13.3 copy number variation syndrome	1/172	23/8085	0.3906	0.3906	0.703915716	871	1

WP3624	WP3624	Lung fibrosis	2/172	64/8085	0.3966	0.3966	0.703915716	6498/4204	2
WP1528	WP1528	Physiological and pathological hypertrophy of the heart	1/172	24/8085	0.4036	0.4036	0.703915716	3977	1
WP325	WP325	Triacylglyceride synthesis	1/172	24/8085	0.4036	0.4036	0.703915716	8613	1
WP334	WP334	GPCRs, class B secretin-like	1/172	24/8085	0.4036	0.4036	0.703915716	23266	1
WP5272	WP5272	LDL- influence on CD14 and TLR4	1/172	24/8085	0.4036	0.4036	0.703915716	7099	1
WP4666	WP4666	Hepatitis B infection	4/172	152/8085	0.4060	0.4060	0.703915716	8503/7048/7099/2033	4
WP536	WP536	Calcium regulation in cardiac cells	4/172	152/8085	0.4060	0.4060	0.703915716	1131/196883/5583/10052	4
WP2324	WP2324	AGE/RAGE pathway	2/172	66/8085	0.4116	0.4116	0.703915716	249/3643	2
WP2857	WP2857	Mesodermal commitment pathway	4/172	154/8085	0.4156	0.4156	0.703915716	23499/659/6926/4091	4
WP2895	WP2895	Differentiation of white and brown adipocyte	1/172	25/8085	0.4163	0.4163	0.703915716	4093	1
WP3668	WP3668	Hypothesized pathways in pathogenesis of cardiovascular disease	1/172	25/8085	0.4163	0.4163	0.703915716	7048	1
WP4585	WP4585	Cancer immunotherapy by PD-1 blockade	1/172	25/8085	0.4163	0.4163	0.703915716	10725	1
WP4842	WP4842	Mammalian disorder of sexual development	1/172	25/8085	0.4163	0.4163	0.703915716	23543	1
WP1403	WP1403	AMP-activated protein kinase signaling	2/172	67/8085	0.4190	0.4190	0.703915716	8503/3643	2
WP5293	WP5293	Acute myeloid leukemia	2/172	67/8085	0.4190	0.4190	0.703915716	8503/3728	2
WP3613	WP3613	Photodynamic therapy-induced unfolded protein response	1/172	27/8085	0.4410	0.4410	0.703915716	3309	1
WP3845	WP3845	Canonical and non-canonical Notch signaling	1/172	27/8085	0.4410	0.4410	0.703915716	84441	1
WP176	WP176	Folate metabolism	2/172	70/8085	0.4410	0.4410	0.703915716	1435/3643	2
WP5130	WP5130	Th17 cell differentiation pathway	2/172	70/8085	0.4410	0.4410	0.703915716	196/5335	2

WP2880	WP2880	Glucocorticoid receptor pathway	2/172	71/8085	0.4482	0.4482	0.703915716	6397/7056	2
WP3851	WP3851	TLR4 signaling and tolerance	1/172	28/8085	0.4529	0.4529	0.703915716	7099	1
WP5121	WP5121	Sphingolipid metabolism in senescence	1/172	28/8085	0.4529	0.4529	0.703915716	10558	1
WP5200	WP5200	Dravet syndrome	1/172	28/8085	0.4529	0.4529	0.703915716	253260	1
WP4255	WP4255	Non-small cell lung cancer	2/172	72/8085	0.4554	0.4554	0.703915716	8503/5335	2
WP4216	WP4216	Chromosomal and microsatellite instability in colorectal cancer	2/172	73/8085	0.4625	0.4625	0.703915716	7048/324	2
WP2361	WP2361	Gastric cancer network 1	1/172	29/8085	0.4646	0.4646	0.703915716	324	1
WP3869	WP3869	Cannabinoid receptor signaling	1/172	29/8085	0.4646	0.4646	0.703915716	196	1
WP179	WP179	Cell cycle	3/172	120/8085	0.4722	0.4722	0.703915716	9184/51433/2033	3
WP3929	WP3929	Chemokine signaling pathway	4/172	166/8085	0.4725	0.4725	0.703915716	8503/5747/5829/1 96883	4
WP2583	WP2583	T cell receptor and co-stimulatory signaling	1/172	30/8085	0.4760	0.4760	0.703915716	5335	1
WP4941	WP4941	GPR143 in melanocytes and retinal pigment epithelium cells	1/172	30/8085	0.4760	0.4760	0.703915716	196883	1
WP530	WP530	Cytokines and inflammatory response	1/172	30/8085	0.4760	0.4760	0.703915716	1435	1
WP4341	WP4341	Non-genomic actions of 1,25 dihydroxyvitamin D3	2/172	75/8085	0.4766	0.4766	0.703915716	7099/5583	2
WP4549	WP4549	Fragile X syndrome	3/172	122/8085	0.4831	0.4831	0.703915716	4204/23405/5335	3
WP2034	WP2034	Leptin signaling pathway	2/172	76/8085	0.4835	0.4835	0.703915716	5747/5335	2
WP2037	WP2037	Prolactin signaling pathway	2/172	76/8085	0.4835	0.4835	0.703915716	5747/5829	2
WP5218	WP5218	Extrafollicular and follicular B cell activation by SARS-CoV-2	2/172	76/8085	0.4835	0.4835	0.703915716	7099/283131	2
WP3858	WP3858	Toll-like receptor signaling related to MyD88	1/172	31/8085	0.4872	0.4872	0.703915716	7099	1
WP3996	WP3996	Ethanol effects on histone modifications	1/172	31/8085	0.4872	0.4872	0.703915716	51564	1

WP4204	WP4204	Tumor suppressor activity of SMARCB1	1/172	31/8085	0.4872	0.4872	0.703915716	5928	1
WP4912	WP4912	SARS coronavirus and innate immunity	1/172	31/8085	0.4872	0.4872	0.703915716	10379	1
WP5122	WP5122	Prostaglandin and leukotriene metabolism in senescence	1/172	31/8085	0.4872	0.4872	0.703915716	3488	1
WP4949	WP4949	16p11.2 proximal deletion syndrome	2/172	77/8085	0.4904	0.4904	0.703915716	58508/2186	2
WP4538	WP4538	Regulatory circuits of the STAT3 signaling pathway	2/172	78/8085	0.4973	0.4973	0.703915716	3977/253260	2
WP2363	WP2363	Gastric cancer network 2	1/172	32/8085	0.4981	0.4981	0.703915716	157769	1
WP3893	WP3893	Development and heterogeneity of the ILC family	1/172	32/8085	0.4981	0.4981	0.703915716	196	1
WP244	WP244	Alpha 6 beta 4 signaling pathway	1/172	33/8085	0.5089	0.5089	0.703915716	5747	1
WP3676	WP3676	BDNF-TrkB signaling	1/172	33/8085	0.5089	0.5089	0.703915716	5335	1
WP4481	WP4481	Resistin as a regulator of inflammation	1/172	33/8085	0.5089	0.5089	0.703915716	5335	1
WP465	WP465	Tryptophan metabolism	1/172	33/8085	0.5089	0.5089	0.703915716	196	1
WP4900	WP4900	Purinergic signaling	1/172	33/8085	0.5089	0.5089	0.703915716	10161	1
WP3971	WP3971	OSX and miRNAs in tooth development	1/172	34/8085	0.5194	0.5194	0.710983321	249	1
WP58	WP58	Monoamine GPCRs	1/172	34/8085	0.5194	0.5194	0.710983321	1131	1
WP3617	WP3617	Photodynamic therapy-induced NF-kB survival signaling	1/172	35/8085	0.5296	0.5296	0.718748139	8837	1
WP1471	WP1471	Target of rapamycin signaling	1/172	36/8085	0.5397	0.5397	0.718748139	253260	1
WP4877	WP4877	Host-pathogen interaction of human coronaviruses - MAPK signaling	1/172	36/8085	0.5397	0.5397	0.718748139	6197	1
WP34	WP34	Ovarian infertility	1/172	37/8085	0.5495	0.5495	0.718748139	23224	1
WP4150	WP4150	Wnt signaling in kidney disease	1/172	37/8085	0.5495	0.5495	0.718748139	4040	1
WP4320	WP4320	Effect of progerin on genes involved in Hutchinson-Gilford progeria syndrome	1/172	37/8085	0.5495	0.5495	0.718748139	5928	1

WP4558	WP4558	Overview of interferons-mediated signaling pathway	1/172	37/8085	0.5495	0.5495	0.718748139	10379	1
WP4698	WP4698	Vitamin D-sensitive calcium signaling in depression	1/172	37/8085	0.5495	0.5495	0.718748139	493	1
WP5269	WP5269	Genetic causes of porto-sinusoidal vascular disease	1/172	37/8085	0.5495	0.5495	0.718748139	2969	1
WP2059	WP2059	Alzheimer's disease and miRNA effects	7/172	329/8085	0.5548	0.5548	0.720229412	8503/1435/5610/5707/324/4040/3643	7
WP15	WP15	Selenium micronutrient network	2/172	87/8085	0.5561	0.5561	0.720229412	57190/3643	2
WP5098	WP5098	T-cell activation SARS-CoV-2	2/172	88/8085	0.5623	0.5623	0.722449005	253260/5335	2
WP4263	WP4263	Pancreatic adenocarcinoma pathway	2/172	89/8085	0.5685	0.5685	0.722449005	8503/7048	2
WP4871	WP4871	Kisspeptin/kisspeptin receptor system in the ovary	1/172	39/8085	0.5686	0.5686	0.722449005	5583	1
WP4336	WP4336	ncRNAs involved in Wnt signaling in hepatocellular carcinoma	2/172	90/8085	0.5746	0.5746	0.722449005	324/4040	2
WP2526	WP2526	PDGF pathway	1/172	40/8085	0.5778	0.5778	0.722449005	5335	1
WP3941	WP3941	Oxidative damage response	1/172	40/8085	0.5778	0.5778	0.722449005	10188	1
WP4564	WP4564	Neural crest cell migration during development	1/172	40/8085	0.5778	0.5778	0.722449005	8503	1
WP138	WP138	Androgen receptor signaling pathway	2/172	91/8085	0.5806	0.5806	0.722449005	5747/2033	2
WP2877	WP2877	Vitamin D receptor pathway	4/172	191/8085	0.5834	0.5834	0.722449005	8853/3488/7056/634	4
WP1433	WP1433	Nucleotide-binding oligomerization domain (NOD) pathway	1/172	41/8085	0.5868	0.5868	0.722449005	55914	1
WP4290	WP4290	Metabolic reprogramming in colon cancer	1/172	42/8085	0.5956	0.5956	0.722449005	2744	1
WP2853	WP2853	Endoderm differentiation	3/172	145/8085	0.6002	0.6002	0.722449005	324/1112/2186	3
WP5224	WP5224	2q37 copy number variation syndrome	3/172	145/8085	0.6002	0.6002	0.722449005	8837/3597/4735	3

WP2911	WP2911	miRNA targets in ECM and membrane receptors	1/172	43/8085	0.6043	0.6043	0.722449005		3672	1
WP4136	WP4136	Fibrin complement receptor 3 signaling pathway	1/172	43/8085	0.6043	0.6043	0.722449005		7099	1
WP4249	WP4249	Hedgehog signaling pathway	1/172	43/8085	0.6043	0.6043	0.722449005		64750	1
WP5198	WP5198	Inflammatory bowel disease signaling	1/172	43/8085	0.6043	0.6043	0.722449005		7099	1
WP4658	WP4658	Small cell lung Fas ligand pathway and stress induction of heat shock	2/172	96/8085	0.6099	0.6099	0.725893637	8503/5747		2
WP314	WP314	proteins ATM signaling in development and disease	1/172	44/8085	0.6128	0.6128	0.725996864		8837	1
WP3878	WP3878	lncRNA in canonical Wnt signaling and colorectal cancer	1/172	45/8085	0.6210	0.6210	0.731969328		55183	1
WP4258	WP4258	Translation inhibitors in chronically activated PDGFRA cells	2/172	99/8085	0.6267	0.6267	0.731969328	324/4040		2
WP4566	WP4566	T cell modulation in pancreatic cancer	1/172	46/8085	0.6291	0.6291	0.731969328		8503	1
WP5078	WP5078	Heart development	1/172	46/8085	0.6291	0.6291	0.731969328		953	1
WP1591	WP1591	Energy metabolism	1/172	47/8085	0.6371	0.6371	0.731969328		659	1
WP1541	WP1541	Pluripotent stem cell differentiation pathway	1/172	48/8085	0.6448	0.6448	0.731969328		2033	1
WP2848	WP2848	Exercise-induced circadian regulation	1/172	48/8085	0.6448	0.6448	0.731969328		1435	1
WP410	WP410	Breast cancer pathway	1/172	48/8085	0.6448	0.6448	0.731969328		5813	1
WP4262	WP4262	GPCRs, other Toll-like receptor signaling pathway	3/172	155/8085	0.6454	0.6454	0.731969328	8503/324/4040		3
WP117	WP117	Translation factors IL-3 signaling pathway	2/172	103/8085	0.6483	0.6483	0.731969328	23266/1131		2
WP75	WP75	Sudden infant death syndrome (SIDS) susceptibility pathways	2/172	103/8085	0.6483	0.6483	0.731969328	8503/7099		2
WP107	WP107	7q11.23 copy number variation syndrome	1/172	50/8085	0.6599	0.6599	0.738769431		5610	1
WP286	WP286		1/172	50/8085	0.6599	0.6599	0.738769431		2889	1
WP706	WP706		3/172	160/8085	0.6666	0.6666	0.739235817	5978/4204/2033		3
WP4932	WP4932		2/172	107/8085	0.6688	0.6688	0.739235817	2969/23476		2

WP4657	WP4657	22q11.2 copy number variation syndrome	2/172	129/8085	0.7650	0.7650	0.780419514	3842/3837	2
WP5039	WP5039	SARS-CoV-2 innate immunity evasion and cell-specific immune response	1/172	68/8085	0.7697	0.7697	0.782170788	2033	1
WP382	WP382	MAPK signaling pathway	4/172	248/8085	0.7791	0.7791	0.788642334	7048/9693/6197/57551	4
WP1982	WP1982	Sterol regulatory element-binding proteins (SREBP) signaling	1/172	71/8085	0.7842	0.7842	0.790830937	3837	1
WP4655	WP4655	Cytosolic DNA-sensing pathway	1/172	74/8085	0.7978	0.7978	0.801486024	103	1
WP4656	WP4656	Joubert syndrome	1/172	76/8085	0.8064	0.8064	0.804064797	4646	1
WP2882	WP2882	Nuclear receptors meta-pathway	5/172	315/8085	0.8065	0.8065	0.804064797	7048/196/6397/7056/2033	5
WP4022	WP4022	Pyrimidine metabolism	1/172	84/8085	0.8373	0.8373	0.823235484	953	1
WP4396	WP4396	Nonalcoholic fatty liver disease	2/172	155/8085	0.8468	0.8468	0.823235484	8503/3643	2
WP2840	WP2840	Hair follicle development: cytodifferentiation - part 3 of 3	1/172	87/8085	0.8476	0.8476	0.823235484	3488	1
WP4298	WP4298	Acute viral myocarditis	1/172	87/8085	0.8476	0.8476	0.823235484	7099	1
WP254	WP254	Apoptosis	1/172	88/8085	0.8508	0.8508	0.823235484	8837	1
WP477	WP477	Cytoplasmic ribosomal proteins	1/172	88/8085	0.8508	0.8508	0.823235484	6197	1
WP5234	WP5234	Bardet-Biedl syndrome	1/172	88/8085	0.8508	0.8508	0.823235484	8239	1
WP2446	WP2446	Retinoblastoma gene in cancer	1/172	90/8085	0.8572	0.8572	0.823235484	5928	1
WP1772	WP1772	Apoptosis modulation and signaling	1/172	92/8085	0.8633	0.8633	0.823235484	8837	1
WP3925	WP3925	Amino acid metabolism	1/172	92/8085	0.8633	0.8633	0.823235484	2744	1
WP69	WP69	T-cell receptor signaling pathway	1/172	92/8085	0.8633	0.8633	0.823235484	5335	1
WP231	WP231	TNF-alpha signaling pathway	1/172	93/8085	0.8662	0.8662	0.823235484	8837	1
WP4746	WP4746	Thyroid hormones production and peripheral downstream signaling effects	1/172	93/8085	0.8662	0.8662	0.823235484	9728	1

WP4963	WP4963	p53 transcriptional gene network	1/172	96/8085	0.8747	0.8747	0.828291739	10379	1
WP2064	WP2064	Neural crest differentiation	1/172	101/8085	0.8876	0.8876	0.837532038	51564	1
WP4536	WP4536	Genes related to primary cilium development (based on CRISPR)	1/172	104/8085	0.8947	0.8947	0.841237486	57534	1
WP2431	WP2431	Spinal cord injury	1/172	121/8085	0.9273	0.9273	0.868818458	7099	1
WP2806	WP2806	Complement system	1/172	124/8085	0.9319	0.9319	0.87005129	22918	1
WP5095	WP5095	Overview of proinflammatory and profibrotic mediators	1/172	129/8085	0.9390	0.9390	0.873541437	1435	1
WP2884	WP2884	NRF2 pathway	1/172	141/8085	0.9531	0.9531	0.883536842	7048	1
WP455	WP455	GPCRs, class A	2/172	263/8085	0.9780	0.9780	0.901003644	1131/10161	2
WP4803	WP4803	rhodopsin-like Ciliopathies	1/172	184/8085	0.9817	0.9817	0.901003644	8239	1
WP702	WP702	Metapathway biotransformation Phase I and II	1/172	185/8085	0.9821	0.9821	0.901003644	9394	1